Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5220656
Max Phase: Preclinical
Molecular Formula: C19H17ClFN5O3
Molecular Weight: 417.83
Associated Items:
ID: ALA5220656
Max Phase: Preclinical
Molecular Formula: C19H17ClFN5O3
Molecular Weight: 417.83
Associated Items:
Canonical SMILES: NC(=O)c1nn(CC(=O)NCC(=O)NCc2cccc(Cl)c2F)c2ccccc12
Standard InChI: InChI=1S/C19H17ClFN5O3/c20-13-6-3-4-11(17(13)21)8-23-15(27)9-24-16(28)10-26-14-7-2-1-5-12(14)18(25-26)19(22)29/h1-7H,8-10H2,(H2,22,29)(H,23,27)(H,24,28)
Standard InChI Key: CUVBWNPHKRAMSM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 417.83 | Molecular Weight (Monoisotopic): 417.1004 | AlogP: 1.36 | #Rotatable Bonds: 7 |
Polar Surface Area: 119.11 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.89 | CX Basic pKa: | CX LogP: 0.92 | CX LogD: 0.92 |
Aromatic Rings: 3 | Heavy Atoms: 29 | QED Weighted: 0.54 | Np Likeness Score: -1.97 |
1. Zhang W, Wu M, Vadlakonda S, Juarez L, Cheng X, Muppa S, Chintareddy V, Vogeti L, Kellogg-Yelder D, Williams J, Polach K, Chen X, Raman K, Babu YS, Kotian P.. (2022) Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors., 74 [PMID:36272185] [10.1016/j.bmc.2022.117034] |
Source(1):